Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WATCHMAN FLX vs anticoagulation after AF ablation
NCT03795298Completed
- Sponsor
- Boston Scientific Corporation
- Start
- May 2019
- Primary completion
- Jul 2024
- Countries
- 10
01
Overview
Randomised, open-label trial (2 arms), sponsored by Boston Scientific Corporation. Primary endpoints: Stroke, All Cause Death, and Systemic Embolism at 1095 days and Non-procedural Bleeding at 1095 days. Started May 2019; status: completed.
Beyond the preview
Go deeper on NCT03795298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795298.